【摘要】 目的:研究以雷贝拉唑和加替沙星为基础的三联疗法作为幽门螺杆菌(HP)感染根除2次以上均失败的补救方案的价值。方法:以雷贝拉唑、加替沙星和进口克拉霉素组成方案,分为7 d疗程组(A组)和14 d疗程组(B组)。60例HP感染根除失败患者随机分为A和B组进行前瞻性研究,应用药物经济学分析两组的C/E比。结果:HP的根除方案的应用仍很不规范。A和B组的根除率分别为75.0%和93.3%(P<0.05)。A和B组的不良反应发生率分别为17.9%和23.3%(P>0.05)。A和B组的C/E比分别为7.44和11.96。结论:以雷贝拉唑、加替沙星为基础的三联疗法作为HP根除失败的补救方案有较高的根除率。更多还原

【Abstract】 Objective: To investigate the effect of rabeprazole and gatifloxacin-based triple therapies after Helicobacter pylori(HP)eradication failure more than 2 times.Methods: The regimens consisted of rabeprazole,gatifloxacin and clarithromycin.Sixty patients with HP eradication failure were randomized into the group A(for 7 days)and B(for 14 days).The cost-effect ratio(C/E)were analysed.Results: The eradication regimens performance was not standarded.The eradication rates of group A and B were 75.0% and 93.3% respectively(P<0.05).The adverse event rates of group A and B were 17.9% and 23.3% respectively(P>0.05).The cost-effect ratios of group A and B were 7.44 and 11.96,respectively.Conclusions: The eradication rate of rabeprazole and gatifloxacin-based triple therapies of HP eradication failure is relatively high.更多还原